Ferumoxytol-enhanced three-dimensional magnetic resonance imaging of carotid atheroma: a feasibility and temporal dependence study

Ammara Usman1, Andrew J. Patterson1, Jianmin Yuan1, Alison Cluroe2, Ilse Patterson1, Martin J. Graves1, Jonathan H. Gillard3,5 & Umar Sadat4,5*

Ferumoxytol is an ultrasmall superparamagnetic particles of iron oxide (USPIO) agent recently used for magnetic resonance (MR) vascular imaging. Other USPIOs have been previously used for assessing inflammation within atheroma. We aim to assess feasibility of ferumoxytol in imaging carotid atheroma (with histological assessment); and the optimum MR imaging time to detect maximum quantitative signal change post-ferumoxytol infusion. Ten patients with carotid artery disease underwent high-resolution MR imaging of their carotid arteries on a 1.5 T MR system. MR imaging was performed before and at 24, 48, 72 and 96 hrs post ferumoxytol infusion. Optimal ferumoxytol uptake time was evaluated by quantitative relaxometry maps indicating the difference in T2* (ΔT2*) and T2 (ΔT2) between baseline and post-Ferumoxytol MR imaging using 3D DANTE MEFGRE qT2*w and iMSDE black-blood qT2,w sequences respectively. 20 patients in total (10 symptomatic and 10 with asymptomatic carotid artery disease) had ferumoxytol-enhanced MR imaging at the optimal imaging window. 69 carotid MR imaging studies were completed. Ferumoxytol uptake (determined by a decrease in ΔT2* and ΔT2) was identified in all carotid plaques (symptomatic and asymptomatic). Maximum quantitative decrease in ΔT2* (10.4 [3.5–16.2] ms, p < 0.001) and ΔT2 (13.4 [6.7–18.9] ms; p = 0.001) was found on carotid MR imaging at 48 hrs following the ferumoxytol infusion. Ferumoxytol uptake by carotid plaques was assessed by histopathological analysis of excised atheroma. Ferumoxytol-enhanced MR imaging using quantitative 3D MR pulse sequences allows assessment of inflammation within carotid atheroma in symptomatic and asymptomatic patients. The optimum MR imaging time for carotid atheroma is 48 hrs after its administration.

Immune-mediated inflammation1 and related neovascularization2 play crucial role in the progression of atherosclerotic disease processes3. Macrophages are the major inflammatory mediators of this process4 which become concentrated at the plaque shoulder and necrotic lipid core that makes the plaque more vulnerable to rupture and thromboembolic sequelaes5.

Magnetic resonance (MR) imaging using targeted contrast medium such as ultrasmall superparamagnetic particles of iron oxide (USPIOs) have demonstrated promising results in investigating the pathophysiology of atherosclerosis6,7 and in the assessment of the effectiveness of anti-atherosclerotic treatments8. The physiochemical properties of USPIOs attribute to their effective uptake by macrophages and their longer plasma half-life makes them suitable for atheroma imaging. The superparamagnetic core of USPIOs alters the magnetic susceptibility by creating an imbalance of the externally applied magnetic field, which in turn leads to signal reduction on T2 and T2*-weighted MR images. The areas containing these particles display rapid transverse relaxation and

1University Department of Radiology, Addenbrooke’s Hospital, Cambridge, CB2 0QQ, UK. 2Department of Pathology, Addenbrooke’s Hospital, Cambridge, CB2 0QQ, UK. 3Christ’s College, Cambridge, CB2 3BU, UK. 4University Department of Surgery, Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK. 5These authors contributed equally: Jonathan H. Gillard and Umar Sadat. *email: us229@cam.ac.uk
pulse sequences were used: T$_1$w images were acquired using a 3D variable refocusing flip angle fast spin echo. Position and fix the coil position. Oncology Systems Ltd, Shrewsbury, United Kingdom) which serves to maintain the head and neck in a comfortable position and fix the coil position. Movement artefact was minimized using a dedicated vacuum-based head restraint system (VAC-LOK Cushion; Healthcare, Waukesha, WI), using a 4-channel phased-array neck coil (PACC, Machnet, Roden, The Netherlands).

Previously, there have been reports of the use of ferumoxytol in assessing arterial wall inflammation in carotid arteries$^{12}$ and in aorta$^{12}$. These studies however did not assess temporal dependence of ferumoxytol i.e. optimal imaging time post administration. Semi quantitative MR pulse sequences were used which also have limitations as discussed below. In the absence of the key temporal dependence information of ferumoxytol (aorta and/or carotid), it has been quite premature to conduct any large scale study$^{14}$, making the methodology of the study flawed and results unreliable.

In this study we aim to:

1. Determine whether ferumoxytol can be used for MR imaging of carotid plaques.
2. Assess the optimum MR imaging time to detect maximum signal change post ferumoxytol administration, using 3D qT$_2$ and qT$_2$*$ imaging.
3. To assess the ferumoxytol enhanced-MR imaging quantified signal drop (representative of underlying plaque inflammation) within carotid atheroma in the patients with symptomatic and asymptomatic carotid artery disease.

Methods

Ten consecutive patients (8 males and 2 females) with moderate to severe duplex-ultrasound confirmed carotid artery disease (i.e. 50–99%) were recruited in the first part of study. Each patient underwent a baseline pre-ferumoxytol MR imaging; and post-ferumoxytol MR imaging was performed at 24, 48, 72 and 96 hrs following infusion for assessing feasibility of this imaging method and to calculate the temporal dependence.

In the second part of this exploratory study, 10 symptomatic and 10 asymptomatic patients with moderate to severe Duplex US confirmed carotid artery disease (i.e. 50–99%) had been recruited in total. Recruitment was consecutive. Among these 20, 10 had already been participants of the initial temporal dependence study. Each patient underwent a baseline pre-ferumoxytol MR imaging; and post-ferumoxytol MR imaging was performed at the optimal MR imaging time as determined by the temporal dependence investigation.

This study was approved by the central Cambridge research ethics research committee. All methods were performed in accordance with the relevant guidelines and regulations. All study participants provided written informed consent.

A >50% internal carotid artery stenosis by duplex ultrasound [based on North American Symptomatic Carotid Endarterectomy Trial criteria] and ability to sign informed consent were necessary requirements for inclusion. Exclusion criteria were (i) history of atopy, asthma or allergic reaction to contrast media, iron or dextran, (ii) known and documented history of haemochromatosis (iii) patients with immune or inflammatory conditions e.g. systemic lupus erythematosus, rheumatoid arthritis (iv) standard MR exclusion criteria.

MR imaging. Imaging was performed on a 1.5 Tesla whole body MR imaging system (MR450w, GE Healthcare, Waukesha, WI), using a 4-channel phased-array neck coil (PACC, Machnet, Roden, The Netherlands). Movement artefact was minimized using a dedicated vacuum-based head restraint system (VAC-LOK Cushion; Oncology Systems Ltd, Shrewsbury, United Kingdom) which serves to maintain the head and neck in a comfortable position and fix the coil position.

Localiser and 2D time-of-flight sequences were performed to locate the carotid bifurcations. The following pulse sequences were used: T$_1$w images were acquired using a 3D variable refocusing flip angle fast spin echo sequence with Delayed Alternating with Nutation for Tailored Excitation blood suppression preparation. qT$_2$* mapping was performed using a multi-echo fast gradient echo sequence using DANTE blood suppression preparation$^{13}$. Six echoes were used as in our experience it is a good balance for the required imaging field of view and matrix size for the carotid study.

Finally, quantitative T2 (qT2) was performed with a multi-echo variable refocusing flip angle FSE sequence with improved Motion-Sensitized Driven-Equilibrium. The accuracy and repeatability of improved Motion-Sensitized Driven-Equilibrium prepared 3D variable refocusing flip angle fast spin echo for T2 mapping has previously been reported$^{16}$. We used three echo times to generate qT2 maps after practical consideration of scanning time and accuracy. We believe that this sequence is the limit in terms of scan time and patient tolerance. This sequence is 3D with high spatial resolution which allows good determination of vessel wall plaque components while keeping the scan time short as short as possible to minimize neck motion.

The detailed parameters of the pulse sequences used are tabulated in the Table 1.
Ferumoxytol administration. Patient’s vital signs (i.e. pulse rate, blood pressure and respiratory rate) were recorded at three-time intervals (within 15 minutes) before the ferumoxytol infusion. The USPIO agent, Ferumoxytol (AMAG, Canada) was obtained as a liquid preparation in 17 ml vials. The agent was further diluted in 250 ml of normal saline and administered as a slow infusion through an indwelling large bore intravenous cannula over 30 minutes. The dose administered was 5 mg/kg. Vitals were monitored every 10 minutes during the infusion and up to 30 min after the ferumoxytol administration. The physiochemical properties and safety data for Ferumoxytol has been published previously11,17,18.

Image analysis. Initial image analysis was performed by the first author (AU) and cross-checked by two experienced MR readers (JHG, US) with greater than 30 yrs combined experience between them. Image quality was rated per vessel for each contrast weighting on a 5-point scale (1 = poor, 5 = excellent) dependant on the overall signal to noise ratio, clarity of the lumen and the vessel wall boundaries. Images with an image quality of ≤2 were excluded from the study.

Pre- and post-USPIO images were manually co-registered according to plaque morphology and distance from the carotid bifurcation at the time of imaging. Slice position relative to the carotid bifurcation were assigned ordinal numbers to enable pre- and post-infusion slice matching. Images were segmented on the first echo of the qT2 and qT2* sequences. Following the identification of the carotid plaque region on T2 and T2* weighted images, the lumen and vessel wall contours were manually drawn using a closed polygon to define the arterial wall ROI using OsirisX (OsirisX 5.5.2, Pixmeo, Geneva, Switzerland). Region of interest (ROI) was defined as a subset of the acquired MR image or a dataset used for identification of carotid plaque region based on morphology and anatomical landmarks.

A region was also drawn in an artefact-free background by the same observer, the standard deviation of this background region was used to quantify noise (defined as $\sigma$). A region was also drawn in the sternocleidomastoid muscle and the mean signal intensity was reported $S_{wall}$. The SNR was calculated using a four-channel phased array correction factor: $SNR_{wall} = 0.659 \times S_{wall}/\sigma^{19}$.

Digital Imaging and Communications in Medicine images were imported into an in-house software developed in Matlab (The Math Works, Version R2013b, Natick, MA, USA) to perform T2* and T2 quantification. ROI files were exported from OsirisX and were imported into in-house Matlab software to generate quantitative relaxometry maps (T2*/R2*, T2/R2) and to calculate the mean T2* and T2 values.

Histological analysis. Carotid plaques of patients scheduled for carotid endarterectomy were retrieved and processed according to the protocol designed by the consultant histopathologist (AC) to assess for the presence of ferumoxytol within atheroma. The specimen was placed in formalin and following overnight fixation place in Ethylenediaminetetraacetic acid for approximately 24 hrs for decalcification if necessary. Subsequently, 3 mm transverse sections were cut through the specimen and multiple slices were processed in a cassette. These processed specimens were embedded in paraffin blocks. From these blocks further 4 sections were cut at 3.5 micrometres. These sections were dehydrated and underwent haematoxylin and eosin (H&E), Perls reagent, elastin van Gieson (EVG) stains and immunostaining for macrophages (CD 68 marker). Histological sections were reviewed by the consultant histopathologist (AC) using a Nikon Eclipse 80i microscope at ×10, ×25 and ×40. Ferumoxytol accumulation was confirmed by Perls’ positive staining and histological sections were classified as positive or negative accordingly.

Statistical analysis. Ferumoxytol uptake was quantified by the absolute change in $T_{2*}$ ($\Delta T_{2*}$) and $T_2$ ($\Delta T_2$) between the pre and post-ferumoxytol MR images measured for each arterial wall segment (ROI) with a decrease

| Contrast weighting | $T_{1w}$ | $qT2*$ | $qT2$ |
|--------------------|---------|-------|-------|
| Sequence           | 3D Variable Refocusing Flip Angle FSE | 3D multi-echo fast gradient echo | 3D Variable Refocusing Flip Angle FSE |
| Acquisition plane  | Axial   | Axial | Axial |
| Blood suppression method | delays alternating with mutation for tailored excitation | delays alternating with mutation for tailored excitation | improved motion sensitive driven equilibrium |
| Echoes per repetition time / echo train length | 24 | 6 | 40 |
| Echo time(s) (ms) | 15.1 | 4.9 | 10.4 | 15.9 | 21.3 | 26.8 | 32.2 |
| Repetition time (ms) | 580 | 58.1 | 2000 |
| Flip angle | variable | 15 | variable |
| Acquisition matrix | $224 \times 224$ | $224 \times 224$ | $224 \times 224$ |
| Acquisition time | $5 \text{ min } 47 \text{ s}$ | $7 \text{ min } 52 \text{ s}$ | $8 \text{ min } 55 \text{ s}$ |
| Field of view (cm) | $14 \times 14$ | $14 \times 14$ | $14 \times 14$ |
| Pixel size (mm) | $0.625 \times 0.625$ | $0.625 \times 0.625$ | $0.625 \times 0.625$ |
| Slice Thickness (mm) | 1.4 | 2.0 | 2.0 |
| Number of excitations | 2 | 1 | 1 |

Table 1. Summary of imaging parameters for the multi-contrast magnetic resonance (MR) imaging protocol at 1.5T.
in $T_2^*$ and $T_2$ values indicating the ferumoxytol uptake. The analysis was quantified twice: whole plaque measurements were derived from all ROIs from slices contain plaque with sufficient image quality, and this process was repeated using only slice matched ROIs across the multiple visits. Continuous variables are presented as median (interquartile range–IQR). Data normality was assessed by Shapiro–Wilk’s test. Paired Wilcoxon Signed Rank Test was used to compare the changes in $T_2$ and $T_2^*$ values relative to baseline examination at each follow-up visit. Spearman’s correlation was used to evaluate the correlation in ferumoxytol uptake at different time frames on both $T_2$ and $T_2^*$ images.

For the comparison between symptomatic and asymptomatic cohort of patients, analyses was performed as above, to obtain whole plaque measurements for the two visits. A paired t-test was used to compare the changes in $T_2$ and $T_2^*$ values relative to baseline and post contrast imaging session and unpaired t-test to compare the difference between the groups. P values $<0.05$ were defined as statistically significant. The statistical analysis was performed in R (version 3.2.1).

Results

Quantitative MR image analysis- feasibility and temporal dependence assessment. Nine of the ten patients completed all of the MR examinations. One patient was unable to attend the final 96 hrs imaging session. The patient demographics and co-morbidities are presented in Table 2. The scheduled 24, 48, 72 and 96 post-infusion scans occurred at $24.6 \pm 2.1$, $48.5 \pm 1.5$, $73.7 \pm 1.6$ and $98.4 \pm 1.7$ hrs post-infusion.

In total 69 carotid MR imaging studies were completed, and MR images used for analyses. Among 10 patients, 18 plaques were identified (10 right-side and 8 left-side). Signal drop was identified in all plaques on $qT_2$ and $qT_2^*$ sequences as shown in Fig. 1.

Mean $T_2$ and $T_2^*$ values of the whole plaque and slice matched location (see Figs. 2 and 3) on subsequent time points relative to baseline were used for statistical analysis. A decrease in $qT_2$ and $qT_2^*$ values was observed between 24–72 hrs with a positive correlation between the $qT_2$ and $qT_2^*$ values at 48 hrs post ferumoxytol infusion ($\text{Spearman’s } r = 0.492$, $p = 0.039$). A significant decrease in $qT_2$ [13.4 [6.2 to 18.9] ms, ($p = 0.001$)] and $qT_2^*$ [10.4 [3.5 to 16.2] ms, ($p < 0.001$)] was observed at 48 hrs post ferumoxytol administration.

Using advanced 3D acquisition techniques, pixel-wise $\Delta T_2/R_2$ and $\Delta T_2^*/R_2^*$ maps ($R_2^*$ is the inverse of the mean $T_2^*$) from the pre and post contrast studies were generated (see Figs. 4 and 5). The median number of pixels per cross-sectional carotid wall area (mm$^2$) was 1762 (Range: 657–3541). The minimum number of pixels per cross-sectional carotid wall area (mm2) was 675 which reduces the possibility of partial volume effect errors considering the small vessel size.

The maximum change in $qT_2$ and $qT_2^*$ relaxation is demonstrated in Tables 3 and 4 respectively. As observed in Table 4, at 72 hrs post ferumoxytol unexpectedly small $qT_2^*$ values were observed which was not in the case in $qT_2$ values at the same time point (Table 3). Being an MR developmental study using a new CM, these unexpected results warrant further investigation in future studies.

The SNR of muscle was also observed to be unaltered between different time points for both $T_2$ and $T_2^*$ weighted imaging.

Histological analysis. The time from USPIO infusion to endarterectomy ranged from 48 hrs to 70 days. Carotid plaques were retrieved from 6 patients scheduled for surgery and from these 15 histological sections containing plaque available for analysis. All the sections were stained with H&E and EVG stains to demonstrate plaque morphology.

Perls-positive staining was observed in 13 sections from 6 of 6 patients demonstrating USPIO in multiple dissociated regions within the plaque, including the FC, LC, plaque shoulder and adventitia of the vessel wall.

| Characteristics                  | n (%)                     |
|----------------------------------|---------------------------|
| Number of patients               | 10                        |
| Male/Female                      | 8/2                       |
| Median age (years) (interquartile range) | 73 (67–75)    |
| Mean luminal stenosis (North American Symptomatic Carotid Endarterectomy Trial) (%) [IQR] | 56.9 (50.2–67.4) |
| TIA/non-disabling stroke         | 10 (100%)                 |
| Hyperlipidaemia                  | 6 (60%)                   |
| Hypertension                     | 7 (70%)                   |
| Diabetes Mellitus                | 2 (20%)                   |
| Peripheral arterial disease      | 2 (20%)                   |
| Previous coronary revascularisation | 1 (10%)              |
| Ischaemic heart disease          | 3 (30%)                   |
| Atrial fibrillation              | 0                         |
| Statin use                       | 10 (100%)                 |
| Clopidogrel                      | 8 (80%)                   |
| Aspirin                          | 6 (60%)                   |
| Current or ex-smoker             | 6 (60%)                   |

Table 2. Patient demographics and comorbidities.
Figure 1. Detailed multi-contrast ferumoxytol-enhanced magnetic resonance imaging protocol of carotid atheroma demonstrating the $qT_2^*$ with six echo times, $qT_1$ with three echo times and $T_1$ pulse sequence at baseline and 48hrs post ferumoxytol administration with corresponding $R_2^*$ and $T_2^*$ maps. This figure illustrates the detailed MR imaging protocol at baseline and 48 hrs after the administration of ferumoxytol in a patient with right internal carotid artery stenosis >70% as calculated by NASCET criteria. Panel [A] shows the multi-echo $T_1^*/R_1^*$ mapping sequence with six echo times and the corresponding $R_1^*$ and $T_1^*$ maps before and at 48 hrs following the administration of ferumoxytol. Panel [B] shows the iMSDE PD and $T_2$ mapping sequence and the corresponding $R_2^*$ and $T_2^*$ maps before and at 48 hrs following the ferumoxytol administration. Panel [C] demonstrates the 3D TOF (time of flight) and $T_1$ images pre-contrast and at 48 hrs of ferumoxytol administration.

Macrophage immunostaining with CD68 antibody marker, co-localised with Perls-positive regions in all the 13 sections from the 6 patients was observed (see Fig. 6). These results support our group previous histopathogical findings using Ferumoxtran-1013. Neovascularisation adjacent to the distribution of the macrophages was also observed hence indicative of the inflammation along with neovessel formation (see Fig. 6).

Ferumoxytol-enhanced MR imaging of patients with symptomatic and asymptomatic carotid artery disease. All patients ($n = 20$) underwent ferumoxytol-enhanced MR imaging of carotid arteries successfully and tolerated the ferumoxytol infusion with no side effects. Patient demographics are presented in Table 5. The two clinical groups of symptomatic and asymptomatic patients had comparable demographics and co-morbidities (Tables 5 and 6). Total imaging time was ~25 minutes.

Signal loss was identified in all plaques on $qT_2$ and $qT_2^*$ sequences. Mean $T_2$ and $T_2^*$ values of the whole plaque on pre- and post-ferumoxytol imaging session were used for statistical analysis.

In both symptomatic ($n = 10$) and asymptomatic ($n = 10$) patient cohorts, we observed a significant decrease in $qT_1$ and $qT_2^*$ values between baseline and 48 hrs post-ferumoxytol MR imaging session ($\Delta T_1^*, p = 0.030$; $\Delta T_2^*, p = 0.003$) and ($\Delta T_2^*, p = 0.002; \Delta T_2^*, p < 0.001$) respectively (see Fig. 7). The SNR of muscle was observed to be unaltered between different time points for both $T_1$ and $T_2^*$ weighted imaging (see Fig. 8). $T_2^*/R_2^*$ maps for an asymptomatic patient are presented in Fig. 9.

Discussion

In this study we report the temporal dependence for ferumoxytol-enhanced MR imaging of human carotid atheroma for the first time in published literature. The feasibility of ferumoxytol in evaluation of carotid atheroma using blood suppressed $qT_1$ and $qT_2^*$ 3D pulse sequences in patients with symptomatic and asymptomatic carotid artery disease is also reported. Previously conducted studies in various vascular territories have used different imaging windows following the ferumoxytol administration12,20, however the optimum MR imaging window post-ferumoxytol remained widely unexplored. We found signal loss occurred between 24–72hrs with a significant statistical correlation between the $qT_1$ and $qT_2^*$ values at 48 hrs post ferumoxytol infusion. This was quantified using an advanced 3D acquisition technique and assessment of $\Delta qT_1$ and $\Delta qT_2^*$ values. The blood suppression technique, DANTE was utilised for $T_2^*$ mapping which is superior to the previously used 2D acquisition methodologies. 3D preparation pulses achieve better blood suppression than 2D pulse sequences and allows 3D acquisition allows larger longitudinal coverage within feasible imaging times with respect to 2D techniques10. Besides, the $T_2^*$ weighted multi-echo fast gradient echo pulse sequence requires high uniformity of the magnetic field, independent of the paramagnetic substance or diamagnetic substance therefore with changes in the
uniformity of the magnetic field, the sequence is sensitive for detection of small lesions. Hence it has the ability to sensitively detect paramagnetic material, such as USPIO.21

This study reports the simultaneous acquisition of qT2 and qT2* 3D pulse sequences and qT2 and qT2* values in assessing the temporal dependency of ferumoxytol-enhanced MR imaging of carotid atheroma. To our knowledge this is the first report in the published literature to have used this comprehensive quantitative analysis for the evaluation of ferumoxytol-enhanced MR imaging in carotid artery territory. Development of this quantitative mapping method has been described by our group previously.15

Previous studies used the semi-quantitative analysis technique to assess the changes in relative signal intensities of the arterial wall normalized for the signal intensity in the adjacent muscle on T2 and T2* weighted images. However, this approach has been criticised as the differences in patient and coil positioning during subsequent imaging sessions may influence signal intensities in plaque area hence may lead to false interpretation of inflammation.22 However, quantitative mapping techniques negate these confounding factors while enhancing the sensitivity of assessment of localisation and amount of USPIO uptake in atherosclerotic tissue. Using an advanced 3D acquisition technique, we were able to generate pixel-wise ΔT2/ΔR2 and ΔT2*/ΔR2* maps (ΔR2* is the inverse of the mean T2*) from the pre and post contrast studies. A similar approach was recently used by another group for carotid imaging.12 We have reported our results as decrease in qT2/qT2* compared to the repeat ability of R2* values and T2* values have been experimentally determined and no evidence of bias was observed.23

We were able to quantify signal loss in all patients who had ferumoxytol-enhanced MR imaging. This positive finding was best visualised using a blood-suppressed 3D T2* weighted MEFGRE sequence between 48–72 hrs after infusion. We observed a decrease in T2/T2* values 24 hrs after USPIO administration. This was however associated with artefacts caused by insufficient blood suppression most likely due to the presence of ferumoxytol

Figure 2. Box and whisker plots of whole plaque and slice matched quantitative T2 and change in quantitative T2 at 24, 48, 72 and 96 hrs post ferumoxytol administration relative to baseline. Figure illustrates the qT2 of (A) whole plaque (C) slice matched location with carotid bifurcation taken as a reference for slice match representing all 10 patients at baseline, 24, 48, 72 and 96 hrs post ferumoxytol administration. (B) Demonstrates the change in whole plaque qT2 at 24, 48, 72 and 96hrs relative to the baseline (p = 0.006), (p < 0.001), (p = 0.002) (p = 0.070) respectively (D) demonstrates the slice matched location change in qT2 at 24, 48, 72 and 96 hrs relative to the baseline (p = 0.053), (p = 0.015), (p = 0.093), (p = 0.770) respectively.
in the blood pool at this time-point. The decreased T₁ of blood after ferumoxytol infusion would likely influence the accuracy of T₂/T₂* measurements at this time-point. The multi-echo fast gradient echo T₂* weighted sequence is also sensitive to the smallest changes in magnetic field, hence when the paramagnetic contrast medium (like ferumoxytol) reaches the neovessel of the atherosclerotic plaque for the first time, the sequence can detect these changes sensitively, which appears as a decrease in signal intensity on this pulse sequence and simultaneous amplification of artefacts caused by insufficient blood suppression due to above reason.

Using a quantitative approach, we observed a significant decrease in T₂ and T₂* values in carotid atheroma 48 hrs after ferumoxytol administration. As a quantitative indicator, the T₂* value is widely used in clinical applications. Besides providing the measurements of the T₂* value of tissues on multi-echo fast gradient echo T₂* weighted imaging it also has the ability to indirectly reflect the iron content of the tissues. The increase in iron content of tissues can cause a shortening in the T₂* relaxation time. This is conducive to quantitatively study iron uptake and deposition. This technique has been previously validated for the quantitative determination of changes in tissue biochemical components. This decrease in T₂* and T₁ was not observed in the adjacent sternocleidomastoid muscle taken as a control. In this study we measured both T₂ and T₂* relativities and found them to be significantly correlated (r = 0.492) post-USPIO infusion at 48 hrs.

This fundamental information about the temporal dependence of ferumoxytol may potentially form the basis of use of this pharmaceutical agent in future studies aimed at assessing pathophysiology of atherosclerosis and atherosclerosis-related inflammation; and in determining efficacy of established and novel anti-atherosclerotic drugs using MR imaging studies.
We also observed that signal loss was still present at 96 hrs imaging in relation to the baseline in our study. This was evident on the decreased $qT_2$ and $qT_2^*$ values at 96 hrs imaging session. Previously conducted studies have shown the washout time for ferumoxytol in another vascular bed of approximately two weeks following the ferumoxytol administration20. As USPIOs are composed of an iron oxide core surrounded by a thick and complete dextran coat having a hydrodynamic size smaller than 50 nm. These particles remain mono-dispersed in solution and are withdrawn from the blood by MPS. The smaller size of these particles facilitates their extravasation through diseased microvessels, where they are engulfed and accumulated by the tissue-resident macrophages within the first 24 hours after the infusion25. Hence this macrophage-selective property allows imaging of vascular inflammation by delayed MR imaging.

Assessment of histological data revealed co-localisation of ferumoxytol and macrophages carotid atheroma. The presence of adjacent prominent neovessel alongside the ferumoxytol aggregation also supports the probable role of the neovessels in promoting macrophage recruitment because iron particles were found both within the adventitia and the plaque area in areas. The exact mechanism of USPIOs uptake is however unknown.

In the second part of this exploratory study it was observed that:

1. In the symptomatic patient cohort, signal loss was observed as significant decrease in $qT_1$ and $qT_2^*$ values and signal loss on $qT_2$ and $qT_2^*$ weighted pulse sequences on post-ferumoxytol MR imaging with $p = 0.030$, $p = 0.003$ respectively. These findings support the initial hypothesis that patients with active disease would have higher macrophage activity and inflammation within atheroma and hence greater uptake of ferumoxytol by these activated macrophages resulting in significant signal drop on MR imaging.

2. It was observed that despite of the asymptomatic status of the study subjects, 90% of asymptomatic plaques demonstrated ferumoxytol uptake in the form of signal loss and decrease in $qT_1$ and $qT_2^*$ values on post-ferumoxytol MR imaging, $p = 0.002$ and $p < 0.001$ respectively. Since most of the patients in the asymptomatic patient cohort had moderate to severe stenosis, these findings may suggest that despite of their asymptomatic disease status for previous 6 months, there may be underlying inflammatory activity.
within atheroma. Also 40% of these patients had ischaemic heart disease, hence it may be inferred that despite of being asymptomatic in carotid territory, the inflammatory activity in the other vascular bed i.e. coronary bed may influence the level of inflammatory activity in carotid atheroma due to systemic inflammatory nature of atherosclerosis. Similar results were observed in previously conducted studies using ferumoxtran-10-enhanced MR imaging6.

3. On comparative quantitative analysis of both symptomatic and asymptomatic patient cohorts on qT2w and qT2* imaging, no statistical significance was observed in this comparison (∆T2, p = 0.220; ∆T2*, p = 0.589 respectively). This is most likely a type 2 error, attributed to the relatively small sample size. Future studies are warranted to investigate this in an adequately powered study.

All patients recruited in this study tolerated the ferumoxytol infusion well with no significant adverse events and completed the consecutive imaging sessions. All the patients were closely monitored for any signs of hypersensitivity after the warning from The Food and Drug Administration on the use of ferumoxytol. We strictly adhered to the precautions as recommended in the guidelines by The Food and Drug Administration for the safe use of ferumoxytol.

**Table 3.** Quantitative T2 (qT2) changes relative to baseline examination at each follow-up visit. *Paired Wilcoxon Signed Rank Test, median [inter-quartiles].

| MR Imaging    | qT2 (ms)       | ∆qT2 (ms)       | p-value |
|---------------|----------------|-----------------|---------|
| Baseline      | 45.8 [39.8 to 56.5] | —               | —       |
| 24hr-post     | 31.6 [28.7 to 36.2] | 13.7 [3.3 to 28.2] | 0.011*  |
| 48hrs-post    | 31.1 [29.0 to 35.7] | 13.4 [6.2 to 18.9] | 0.001*  |
| 72hrs-post    | 31.7 [28.8 to 38.2] | 12.6 [2.6 to 22.2] | 0.005*  |
| 96 hrs-post   | 34.9 [33.7 to 42.5] | 10.5 [1.9 to 17.8] | 0.015*  |

**Figure 5.** Ferumoxytol-enhanced magnetic resonance images of carotid atheroma with corresponding T2*/R2* maps and T2* graphs at baseline and 24, 48, 72 and 96 hrs of ferumoxytol administration demonstrating the maximum R2* increase of the atherosclerotic plaque after ferumoxytol administration at 48 hrs. [A] Images of the multi-echo T2*/R2* MR sequence at all 5 time points with signal void in carotid atheroma (yellow arrow) visible at 48 hrs following ferumoxytol administration. [B] Shows corresponding R2* maps (mean R* values) pre-contrast and at 24hr, 48hr, 72hr and 96hr following ferumoxytol administration. Note the maximum R2* increase of the atherosclerotic plaque after ferumoxytol administration at 48hrs, reflecting USPIO uptake. [C,D] Shows the corresponding T2* maps and graphs demonstrating maximum decrease in T2* values at 48 hr.
administration of this infusion. The safety data regarding the administration of ferumoxytol in our study further strengthen the potential use of USPIOs for vessel wall imaging. Given the availability of superparamagnetic iron oxide, ferumoxytol-enhanced MR imaging avoids the risk of nephrogenic systemic fibrosis, which has been associated with the administration of gadolinium-based contrast media, hence it could be a good alternative for vascular imaging as supported by the recently conducted trials26,27.

Limitations
One of the potential issues relating to the uptake of ferumoxytol by macrophages is that the resulting susceptibility artefact may preclude short-term follow-up with other diagnostic MR imaging sequences; this issue may be of particular concern for follow-up hepatic or oncologic imaging because ferumoxytol can persist in macrophages for up to 2 months28. Also complete wash out of the previous dose of USPIO, allowing baseline T$_2^*$

| MR Imaging | qT$_2^*$ (ms) | $\Delta$qT$_2^*$ (ms) | p-value |
|------------|---------------|----------------------|---------|
| Baseline   | 23.7 [19.9 to 25.4] | —                    | —       |
| 24hr-post  | 9.0 [6.9 to 13.6]   | 12.9 [9.5 to 16.4]   | <0.001* |
| 48hrs-post | 12.4 [8.3 to 15.7]  | 10.4 [3.5 to 16.2]   | <0.001* |
| 72hrs-post | 16.3 [10.6 to 28.0] | 0.2 [-8.2 to 5.2]    | 0.832*  |
| 96hrs-post | 12.9 [11.3 to 17.0] | 8.7 [-0.5 to 12.2]   | 0.053*  |

Table 4. Quantitative T$_2^*$ (qT$_2^*$) changes relative to baseline examination at each follow-up visit. *Paired Wilcoxon Signed Rank Test, median [inter-quartiles].

Figure 6. (a) Iron within ferumoxytol stained blue on Perl's stain- back arrows (at 20 × magnification). (b) Immunohistochemical staining of macrophages (CD68) demonstrates the co-localization of the macrophages (black arrows) in the area corresponding to the ferumoxytol uptake on Perl's stain (a). Neovessels (blue star) seem to be in vicinity of areas abundant in macrophages.
to return to normal is essential to reassess uptake of USPIO accurately, without impact from previous USPIO administration20.

Other limitations include. (1) image quality affected by poor blood suppression as ferumoxytol remains intravascularly within first 24 hrs, hence imaging quality between 24–36 hrs is markedly affected till the time it is taken up intracellularly; (2) the decrease in T1 of blood following ferumoxytol administration may affect the accuracy of R2* measurements; (3) An additional patient visit posing a logistical limitation with MRI scheduling; (4) Inter-reader and Intrareader reproducibility was not assessed in this study. The lack of formal blinding of imaging prior to analysis was also a limitation. Future studies are warranted to assess this. (5) The second part of this study, being exploratory in nature, had small sample size. This was designed as a pilot study primarily to assess the feasibility of ferumoxytol-enhanced MR imaging in patients with symptomatic and asymptomatic disease. (6) There was variable duration between a patient undergoing carotid MR and carotid endarterectomy (maximum 70 days). This delay in obtaining the carotid sample for histological assessment may have affected some histology findings, however we consistently noted co-localisation of Perl’s stained iron with areas containing CD68 stained macrophages. (8) There were only 2 female patients in our study sample. It remains predominantly an unanswered question about how the immune mechanistics differs between men and women regarding atherosclerosis29, and its implications for imaging studies using iron oxide contrast media for investigating atherosclerosis related inflammation.

### Table 5. Patient demographics.

| Characteristics                  | n (%)   |
|----------------------------------|---------|
| Number of patients               | 20      |
| Male/ Female                     | 17/3    |
| Median age (years) (IQR)         | 71 (66–75) |
| Mean luminal stenosis (North American Symptomatic Carotid Endarterectomy Trial) (%) (IQR) | 58.7 (51.4–64.4) |
| Previous TIA (6 months ago) or asymptomatic | 10 (50%) |
| Recent TIA/ nondisabling stroke  | 10 (50%) |
| Hyperlipidaemia                  | 10 (50%) |
| Hypertension                     | 17 (85%) |
| Diabetes Mellitus                | 5 (25%)  |
| Peripheral arterial disease      | 2 (10%)  |
| Previous coronary revascularisation | 2(10%)  |
| Ischaemic heart disease          | 5 (25%)  |
| Atrial fibrillation              | 0       |
| Statin                           | 20 (100%) |
| Clopidogrel                      | 14 (70%) |
| Aspirin                          | 14 (70%) |
| Current or ex-smoker             | 13 (65%) |

### Table 6. Comparison of the demographics and comorbidities of patients with symptomatic and asymptomatic carotid artery disease. *Chi-square, †Mann-Whitney Test.

| Characteristics                  | Symptomatic carotid artery disease (n = 10) | Asymptomatic carotid artery disease (n = 10) | p-value (two-tailed) |
|----------------------------------|---------------------------------------------|---------------------------------------------|---------------------|
| Age (years)                      | 70.5 (66.5–75.2)                             | 70 (66–75.5)                                | 0.548†              |
| Vascular events (TIA/Stroke)     | 10 (100%)                                    | 4 (40%)                                     | 0.014*              |
| Ischemic heart disease           | 2 (20%)                                      | 4 (40%)                                     | 0.62*               |
| Carotid endarterectomy           | 4 (40%)                                      | 4 (40%)                                     | 1.00*               |
| Hypertension                     | 9 (90%)                                      | 8 (80%)                                     | 0.53*               |
| Hyperlipidaemia                  | 8 (80%)                                      | 4 (40%)                                     | 0.53*               |
| Diabetes                         | 3 (30%)                                      | 2 (20%)                                     | 0.60*               |
| Statin                           | 10 (100%)                                    | 10 (100%)                                   | 1.00*               |
| Clopidogrel                      | 10 (100%)                                    | 4 (40%)                                     | 0.02*               |
| Aspirin                          | 9 (90%)                                      | 5 (50%)                                     | 0.14*               |
| Angiotensin-converting enzyme inhibitor-Inhibitor | 4 (40%)                                   | 3 (30%)                                     | 0.63*               |
Figure 7. Box and whisker plots illustrate the Ferumoxytol uptake by symptomatic and asymptomatic patient cohort at baseline and 48 hrs post ferumoxytol MR imaging (A) the $\Delta T_2$ values, $p = 0.030$, $p = 0.002$ for symptomatic and asymptomatic patient cohort respectively. (B) The $\Delta T_2^*$values, $p = 0.003$, $p < 0.001$ for symptomatic and asymptomatic cohort respectively.

Figure 8. Box and whisker plots illustrate signal-to-noise ratio muscle on $qT_2^*$ and $qT_2$ weighted sequences at pre and 48hrs post ferumoxytol MR imaging (A) SNR muscle on $qT_2^*$ weighted sequence (B) SNR muscle on $qT_2$ weighted sequence at baseline and 48 hrs post-ferumoxytol MR imaging sessions.
This study demonstrates the feasibility and temporal dependence of ferumoxytol-enhanced MR imaging of carotid atheroma. This was visualised as foci of signal reduction that are attributed to ferumoxytol uptake by macrophages which was evident on histopathological assessment. The optimum imaging window with maximum signal drop during serial MR imaging sessions was identified to be 48 hrs post ferumoxytol infusion. The precise quantifiable indicators such as T2* relaxation time may prove to be more conducive for the quantitative evaluation of the physiological/pathological status of the tissues. These preliminary results are encouraging and offer a rationale to conduct further investigation on larger patient cohorts.

The fundamental information about the temporal dependence of ferumoxytol may potentially form the basis of use of this pharmaceutical agent in future studies aimed at assessing pathophysiology of atherosclerosis and atherosclerosis-related inflammation; and in determining efficacy of established and novel anti-atherosclerotic drugs using MR imaging studies.

Data availability
Authors agree to making materials, data and associated protocols promptly available to readers without undue qualifications in material transfer agreements as required.

Received: 29 August 2019; Accepted: 1 January 2020;
Published online: 04 February 2020

References
1. Libby, P., Lichtman, A. H. & Hansson, G. K. Immune effector mechanisms implicated in atherosclerosis: from mice to humans. *Immunol. 38*, 1092–1104 (2013).
2. Moreno, P. R., Purushothaman, M. & Purushothaman, K. R. Plaque neovascularization: defense mechanisms, betrayal, or a war in progress. *Ann. N. Y. Acad. Sci. 1254*, 7–17 (2012).
3. Sadat, U. *et al.* Inflammation and neovascularization intertwined in atherosclerosis: imaging of structural and molecular imaging targets. *Circulation 130*, 786–794 (2014).
4. Chinetti-Gbaguidi, G., Collin, S. & Staels, B. Macrophage subsets in atherosclerosis. *Nat. Rev. Cardiol. 12*, 10–17 (2015).
5. Falk, E., Nakano, M., Bentzon, J. F., Finn, A. V. & Virmani, R. Update on acute coronary syndromes: the pathologists’ view. *Eur. Heart J. 34*, 719–728 (2013).
6. Tang, T. Y. et al. Comparison of the inflammatory burden of truly asymptomatic carotid atheroma with atherosclerotic plaques in patients with asymptomatic carotid stenosis undergoing coronary artery bypass grafting: an ultrasmall superparamagnetic iron oxide enhanced magnetic resonance study. *Eur. J. Vasc. Endovasc. Surg.* 35, 392–398 (2008).

7. Trivedi, R. A., U-King-Im, J. M., Graves, M. J., Kirkpatrick, P. J. & Gillard, J. H. Noninvasive imaging of carotid plaque inflammation. *Neuroradiology* 53, 187–188 (2004).

8. Tang, T. Y. et al. The Atheroma (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study: Evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease. *J. Am. Coll. Cardiol.* 53, 2039–2050 (2009).

9. Trivedi, R. A. et al. *In vivo* detection of macrophages in human carotid atheroma: temporal dependence of ultrasmall superparamagnetic particles of iron oxide-enhanced MRI. *Stroke* 35, 1631–1635 (2004).

10. Tang, T. Y. et al. Temporal dependence of *in vivo* USPIO-enhanced MRI signal changes in human carotid atheromatous plaques. *Neuroradiology* 51, 457–465 (2009).

11. Weinstein, J. S. et al. Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review. *J. Cereb. Blood Flow. Metab.* 30, 15–35 (2010).

12. Smits, L. P. et al. Evaluation of ultrasmall superparamagnetic iron oxide (USPIO) enhanced MRI with ferumoxytol to quantify arterial wall inflammation. *Atherosclerosis* 263, 211–218 (2017).

13. McBride, O. M. et al. Positron Emission Tomography and Magnetic Resonance Imaging of Cellular Inflammation in Patients with Abdominal Aortic Aneurysms. *Eur. J. Vasc. Endovasc. Surg.* 51, 518–526 (2016).

14. Investigators, M. R. S. Aortic Wall Inflammation Predicts Abdominal Aortic Aneurysm Expansion, Rupture, and Need for Surgical Repair. *Circulation* 136, 787–797 (2017).

15. Yuan, J. et al. The development and optimisation of 3D black-blood R2* mapping of the carotid artery wall. *Magn. Reson. Imaging* 44, 104–110 (2017).

16. Yuan, J. et al. A Comparison of Black-blood T2 Mapping Sequences for Carotid Vessel Wall Imaging at 3T: An Assessment of Accuracy and Repeatability. *Magn. Reson. Med. Sci.* 18, 29–35 (2019).

17. Spinowitz, B. S. et al. Ferumoxytol for treating iron deficiency anemia in CKD. *J. Am. Soc. Nephrol.* 19, 1599–1605 (2008).

18. Dosa, E. et al. MRI using ferumoxytol improves the visualization of central nervous system vascular malformations. *Stroke* 42, 1581–1588 (2011).

19. Constantinides, C. D., Atalar, E. & McVeigh, E. R. Signal-to-noise measurements in magnitude images from NMR phased arrays. *Magn. Reson. Med.* 38, 852–857 (1997).

20. Stirrat, C. G. et al. Ferumoxytol-enhanced magnetic resonance imaging assessing inflammation after myocardial infarction. *Heart* 103, 1328–1335 (2017).

21. Yang, Y. M. et al. Comparison of USPIO-enhanced MRI and Gd-DTPA enhancement during the subacute stage of focal cerebral ischemia in rats. *Acta Radiol.* 55, 864–873 (2014).

22. Fayad, Z. A., Razzouk, L., Briley-Saebo, K. C. & Mani, V. Iron oxide magnetic resonance imaging for atherosclerosis therapeutic evaluation: still “rusty”? *J. Am. Coll. Cardiol.* 53, 2051–2052 (2009).

23. Alam, S. R. et al. Ultrasmall superparamagnetic particles of iron oxide in patients with acute myocardial infarction: early clinical experience. *Circ. Cardiovasc. Imaging* 5, 559–565 (2012).

24. Lin, Z. C., Zhai, L., Chne, Y. P. & Zhang, X. L. Clinical application of T2*GRE multiple echo sequence on articular cartilage disease in the knee. *Nan Fang Yi Ke Da Xue Xue Bao* 31, 1095–1100 (2011).

25. Hasan, D. M. et al. Macrophage imaging within human cerebral aneurysms wall using ferumoxytol-enhanced MRI: a pilot study. *Arterioscler. Thromb. Vasc. Biol.* 32, 1032–1038 (2012).

26. Neuwelt, E. A. et al. Ultrasound superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)? *Kidney Int.* 75, 465–474 (2009).

27. Mukundan, S. et al. Ferumoxytol-Enhanced Magnetic Resonance Imaging in Late-Stage CKD. *Am. J. Kidney Dis.* 67, 984–988 (2016).

28. Ittrich, H., Peldschus, K., Raabe, N., Kaul, M. & Adam, G. Superparamagnetic iron oxide nanoparticles in biomedicine: applications and developments in diagnostics and therapy. *Rofo* 185, 1149–1166 (2013).

29. Fairweather, D. Sex differences in inflammation during atherosclerosis. *Clin. Med. Insights Cardiol.* 8, 49–59 (2014).

**Acknowledgements**

Dr. Ammara Usman is supported by the Mountbatten Cambridge International Scholarship in collaboration with Christ’s College & the Sir Ernest Cassel Educational Trust.

**Author contributions**

Design of the work A.U., A.J.P., J.Y., A.C., I.P., M.J.G., J.H.G., U.S.; Data acquisition A.U., A.J.P., J.Y., A.C., I.P., M.J.G., U.S., Data analysis A.U., A.J.P., A.C., M.J.G., J.H.G., Drafting the manuscript A.U., A.J.P., J.Y., I.P., M.J.G., J.H.G., U.S. All above authors have approved the submitted version, and have agreed both to personally accountable for the author’s own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature.

**Competing interests**

The authors declare no competing interests.

**Additional information**

Correspondence and requests for materials should be addressed to U.S.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
